Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 25, Issue 12, Pages 1682-1685Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458519852100
Keywords
Dimethyl fumarate; progressive multifocal leukoencephalopathy; multiple sclerosis; lymphopenia; risk stratification
Categories
Ask authors/readers for more resources
Background: Progressive multifocal leukoencephalopathy (PML) is the main safety concern for dimethyl fumarate (DMF) treatment in persons with multiple sclerosis (pwMS). Risk stratification under DMF is currently based on age above 50 years and prolonged lymphopenia below 500 cells/mu L. Objective: To report a case of PML under DMF without severe lymphopenia or immunosenescence. Methods: Case report. Results: A 39-year-old female pwMS developed DMF-associated oligosymptomatic PML. The patient had not experienced any repeated lymphocyte counts below 800 cells/mu L and was 15 years younger than previously described cases. Conclusion: Despite risk stratification, vigilance for PML is advised in all pwMS under DMF. Severe CD8-lymphopenia is a common feature of all published DMF-associated cases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available